Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: A cohort study from an endemic area

2015 ◽  
Vol 181 ◽  
pp. 27-29 ◽  
Author(s):  
Ming-Shian Tsai ◽  
Yao-Chun Hsu ◽  
Po-Chin Yu ◽  
Cheng-Li Lin ◽  
Chia-Hung Kao
Keyword(s):  
Acute Coronary Syndrome ◽  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Endemic Area ◽  
Antiviral Treatment ◽  
Coronary Syndrome

P6406Platelet reactivity in Hepatitis C virus infected patients on dual antiplatelet therapy for acute coronary syndrome

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
F Scudiero ◽  
R Valenti ◽  
R Marcucci ◽  
G D Sanna ◽  
A M Gori ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Platelet Reactivity ◽  
Multivariable Analysis ◽  
Hcv Infection ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Coronary Syndrome

Abstract Background Coronary artery disease (CAD) has been recognized as a serious and potentially life-threatening complication of Hepatitis C Virus (HCV) infection. High on treatment platelet reactivity has been associated with high risk of ischemic events in patients with CAD, but data regarding the association with HCV infection are still lacking. Purpose We sought to assess platelet reactivity on dual anti-platelet therapy and long-term outcome of acute coronary syndrome (ACS) patients infected with HCV. Methods ACS patients infected with HCV were matched to ACS patients without HCV for age, sex, diabetes, hypertension and renal function. Primary and secondary study endpoints were the proportion of patients with high on treatment platelet reactivity (HTPR) and long-term outcomes, respectively. Results HCV-infected ACS patients had higher levels of platelet reactivity (ADP10-LTA: 56% ± 18% vs. 44% ± 22%; p=0.002; Arachidonic Acid-LTA: 25% ± 21% vs. 16% ± 15%; p=0.011) and higher rate of HTPR on clopidogrel and aspirin compared with non-HCV patients. Multivariable analysis demonstrated HCV-infection to be an independent predictor of HTPR. At follow-up, estimated major adverse clinical events (MACE: cardiac death, non fatal myocardial infarction and any revascularization) were 57% vs. 37%, p=0.006 in HCV-infected ACS and non-HCV, respectively. Also, TIMI major bleeding rates were higher in HCV-infected subjects (11% vs. 3%; p=0.043) as compared with non-infected patients. Platelet function according to HCV status Conclusions ACS patients with HCV infection have increased on treatment platelet reactivity, higher rate of HTPR, MACE and bleedings as compared with non-HCV patients.

scholarly journals Platelet Reactivity in Hepatitis C Virus–Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome

2020 ◽  
Vol 9 (18) ◽  
Author(s):  
Fernando Scudiero ◽  
Renato Valenti ◽  
Rossella Marcucci ◽  
Giuseppe D. Sanna ◽  
Anna Maria Gori ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Platelet Reactivity ◽  
Hcv Infection ◽  
Light Transmittance ◽  
Coronary Syndrome ◽  
Light Transmittance Aggregometry

Background Coronary artery disease (CAD) has been recognized as a serious and potentially life‐threatening complication of Hepatitis C Virus (HCV) infection. High on‐treatment platelet reactivity has been associated with high risk of ischemic events in patients with CAD, but data regarding the association with HCV infection are still lacking. This post hoc analysis aims to assess high on‐treatment platelet reactivity, severity of CAD, and long‐term outcomes of patients with acute coronary syndrome (ACS) who were infected with HCV. Methods and Results Patients with ACS who were infected with HCV (n=47) were matched to patients with ACS and without HCV (n=137) for age, sex, diabetes mellitus, hypertension, and renal function. HCV‐infected patients with ACS had higher levels of platelet reactivity (ADP 10 –light transmittance aggregometry, 56±18% versus 44±22% [ P =0.002]; arachidonic acid–light transmittance aggregometry, 25±21% versus 16±15% [ P =0.011]) and higher rates of high on‐treatment platelet reactivity on clopidogrel and aspirin compared with patients without HCV. Moreover, HCV‐infected patients with ACS had higher rates of multivessel disease (53% versus 30%; P =0.004) and 3‐vessel disease (32% versus 7%; P <0.001) compared with patients without HCV. At long‐term follow‐up, estimated rates of major adverse cardiovascular events (cardiac death, nonfatal myocardial infarction, and ischemia‐driven revascularization) were 57% versus 34% ( P =0.005) in HCV‐ and non–HCV‐infected patients with ACS, respectively. In addition, thrombolysis In Myocardial Infarction (TIMI) major bleeding rates were higher in HCV‐infected patients (11% versus 3%; P =0.043) compared with noninfected patients. Multivariable analysis demonstrated that HCV infection was an independent predictor of high on‐treatment platelet reactivity, severity of CAD, and long‐term outcome. Conclusions In this hypothesis‐generating study, patients with ACS and HCV infection showed increased on‐treatment platelet reactivity, more severe CAD, and worse prognosis compared with patients without HCV.

scholarly journals Maternal Hepatitis B Virus or Hepatitis C Virus Carrier Status and Long-Term Endocrine Morbidity of the Offspring—A Population-Based Cohort Study

2020 ◽  
Vol 9 (3) ◽  
pp. 796 ◽  
Author(s):  
Naim Abu Freha ◽  
Tamar Wainstock ◽  
Tzvi Najman Menachem ◽  
Eyal Sheiner
Keyword(s):  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Cox Regression ◽  
Population Based ◽  
Carrier Status ◽  
B Virus

This study aimed to investigate the long-term effect of maternal hepatitis B virus (HBV) or hepatitis C virus (HCV) carrier status on offspring endocrine morbidity. A population-based cohort study included all singleton deliveries between the years 1991–2014 at the Soroka University Medical Center, Beer-Sheva, Southern Israel. The mothers were subdivided into three groups, HBV carriers, HCV carriers and non-carriers. Data regarding the long-term endocrine morbidity of their offspring were compared between the groups. The study included 242,905 (99.7%) non-carrying mothers, 591 (0.2%) mothers who were carriers for HBV and 186 (0.1%) mothers who were carriers for HCV. The Kaplan–Meier’s survival curve demonstrated a significantly higher cumulative endocrine morbidity in children born to mothers with HCV (log-rank test, p = 0.002). Specifically, higher rates of hypoglycemia were noted among the offspring born to mothers who were carriers of HCV (1.1%; p = 0.001) compared with the offspring of mothers who were either carriers of HBV (0.2%) or non-carriers (0.1%). A Cox regression model controlled for maternal age, gestational age, maternal diabetes, hypertensive disorders of pregnancy, found maternal HCV carrier status to be independently associated with pediatric endocrine morbidity in the offspring (adjusted hazard ratio = 5.05, 95% CI: 1.625–15.695, p = 0.005). Maternal HCV carrier status is an independent risk factor for long-term endocrine morbidity.

scholarly journals Effect of cardiac rehabilitation on 24-month all-cause hospital readmissions: A prospective cohort study

2018 ◽  
Vol 18 (3) ◽  
pp. 234-244 ◽  
Author(s):  
Emma Thomas ◽  
Mojtaba Lotfaliany ◽  
Sherry L Grace ◽  
Brian Oldenburg ◽  
C Barr Taylor ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Cohort Study ◽  
Length Of Stay ◽  
Cardiac Rehabilitation ◽  
Hospital Readmission ◽  
Hospital Admissions ◽  
P Value ◽  
Post Discharge ◽  
Coronary Syndrome

Background: Ageing populations and increasing survival following acute coronary syndrome has resulted in large numbers of people living with cardiovascular disease and at high risk of hospitalizations. Rising hospital admissions have a significant financial cost to the healthcare system. Aim: The purpose of this study was to determine whether cardiac rehabilitation is protective against long-term hospital readmission (frequency and length) following acute coronary syndrome. Methods: Data from 416 Australian patients with acute coronary syndrome enrolled in the Anxiety Depression and heart rate Variability in cardiac patients: Evaluating the impact of Negative emotions on functioning after Twenty four months (ADVENT) prospective cohort study between January 2013–June 2014 was analyzed secondarily. Participants self-reported cardiac rehabilitation attendance over the 12 months post-discharge. All-cause readmission data were extracted from hospital records 24 months post-index event. The association between cardiac rehabilitation and all-cause readmission, frequency of readmissions, and length of stay was assessed using three methods (a) regression analysis, (b) propensity score matching, and (c) inverse probability treatment weighting. Results: Overall, 416 patients consented (53% of eligible patients), of which 414 (99.5%) survived the first 30 days post-discharge and were included in the analysis. Medical records were located for 409 participants after 24 months (98% follow-up rate). In total, 267 (65%) reported attending cardiac rehabilitation; there were 392 readmissions by 239 patients. Cardiac rehabilitation attendance was not associated with all-cause hospital readmission; however, it was associated with lower frequency of hospital admissions (odds ratio 0.53, 95% confidence interval: 0.31–0.91 p-value:0.022) and length of stay (coefficient –1.21 days, 95% confidence interval: –2.46–0.26; marginally significant p-value: 0.055) in adjusted models. Conclusion: This study substantiates the long-term benefits of cardiac rehabilitation on readmissions, including length of stay, which would result in lower costs to the healthcare system.

Acute coronary syndrome and long-term exposure to air pollution: a cohort study

2011 ◽  
Vol 2011 (1) ◽  
Author(s):  
Zorana J. Andersen ◽  
Sara Ø Brebbia ◽  
Klaus Kaae Andersen ◽  
Martin Hvidberg ◽  
Steen S. Jensen ◽  
...  
Keyword(s):  
Air Pollution ◽  
Acute Coronary Syndrome ◽  
Cohort Study ◽  
Coronary Syndrome

Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study

2009 ◽  
Vol 16 (9) ◽  
pp. 659-665 ◽  
Author(s):  
N. Hansen ◽  
N. Obel ◽  
P. B. Christensen ◽  
H. Krarup ◽  
A. L. Laursen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Initiation ◽  
Antiviral Treatment ◽  
Danish Cohort

scholarly journals Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

2018 ◽  
Vol 5 (6) ◽  
Author(s):  
David L Wyles ◽  
Minhee Kang ◽  
Roy M Matining ◽  
Robert L Murphy ◽  
Marion G Peters ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
High Risk ◽  
Viral Hepatitis ◽  
Low Risk ◽  
Hepatitis C Infection ◽  
Recurrence Rates ◽  
Viral Hepatitis C

Abstract Hepatitis C virus (HCV) recurrence rates were similar between those with HCV/HIV co-infection (0.35/100 person-years) and HCV infection (0.42/100 person-years). Low rates of recurrence likely represent enrollment of an HIV population at low risk for recurrence. Care should be taken not to label all HCV/HIV co-infected patients as being at high risk for HCV recurrence.

Sign in / Sign up

Export Citation Format

Share Document